New hope for breast cancer patients with brain tumors: targeted drug shows promise

NCT ID NCT06048718

Ongoing Disease control Sponsor: MedSIR Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called trastuzumab-deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants receive the drug intravenously, and doctors monitor tumor response using brain scans. This is a phase 2 trial, meaning it is still being studied for safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

Hospital Arnau de Vilanova de Valencia

Valencia, Valencia, 46015, Spain
Hospital Beata María Ana

Madrid, Madrid, 28007, Spain
Hospital Clínico Universitario de Valencia

Valencia, Valencia, 46010, Spain
Hospital Universitari Dexeus

Barcelona, Barcelona, 08028, Spain
Hospital Universitari Vall D'Hebron

Barcelona, Barcelona, 08035, Spain
Hospital Universitario Clínico San Cecilio de Granada

Granada, Granada, 18016, Spain
Hospital Universitario Ramón y Cajal

Madrid, Madrid, 28034, Spain
Hospital Universitario Reina Sofía

Córdoba, Córdoba, 14004, Spain
Hospital Universitario San Juan de Alicante

Alicante, Alicante, 03550, Spain
Hospital Universitario Virgen del Rocío

Seville, Sevilla, 41013, Spain
Hospital Universitario de Basurto

Bilbao, Bilbao, 48013, Spain
Medical University of Vienna

Vienna, 1090, Austria
Salzburg Cancer research Institute-Center

Salzburg, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.